Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos N Papandreou

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
International Journal of Oncology|November 29, 2018
Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic cancer modelKonstantinos Kamposioras, Chrysiida Tsimplouli, Caroline Verbeke, et al.
Anticancer Research|October 3, 2014
Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology GroupVasilios Karavasilis, Paris Kosmidis, Konstantinos N Syrigos, et al.
Journal of Neuro-Oncology|July 9, 2017
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG)Christos Christodoulou, Anna Kalogera-Fountzila, Vasilios Karavasilis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancerChristos N Papandreou, Danai D Daliani, Darrell Nix, et al.
BMC Cancer|July 4, 2012
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysisDimitrios Pectasides, George Papaxoinis, Konstantine T Kalogeras, et al.
BMC Cancer|July 17, 2014
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trialGeorge Fountzilas, Urania Dafni, Christos Papadimitriou, et al.
Anticancer Research|August 27, 2011
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluationGeorge Fountzilas, Helen P Kourea, Mattheos Bobos, et al.
World Journal of Urology|July 11, 2016
Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patientsMichalis Liontos, Eleni-Andriana Trigka, Penelope Korkolopoulou, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
International Journal of Oncology|November 29, 2018
Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic cancer modelKonstantinos Kamposioras, Chrysiida Tsimplouli, Caroline Verbeke, et al.
Anticancer Research|October 3, 2014
Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology GroupVasilios Karavasilis, Paris Kosmidis, Konstantinos N Syrigos, et al.
Journal of Neuro-Oncology|July 9, 2017
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG)Christos Christodoulou, Anna Kalogera-Fountzila, Vasilios Karavasilis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancerChristos N Papandreou, Danai D Daliani, Darrell Nix, et al.
BMC Cancer|July 4, 2012
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysisDimitrios Pectasides, George Papaxoinis, Konstantine T Kalogeras, et al.
BMC Cancer|July 17, 2014
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trialGeorge Fountzilas, Urania Dafni, Christos Papadimitriou, et al.
Anticancer Research|August 27, 2011
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluationGeorge Fountzilas, Helen P Kourea, Mattheos Bobos, et al.
World Journal of Urology|July 11, 2016
Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patientsMichalis Liontos, Eleni-Andriana Trigka, Penelope Korkolopoulou, et al.
Pageof 6